Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.61+5.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GALT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GALT — earnings miss
Dated 2026-08-14
Results of Operations and Financial Condition. On August 14, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…
Why it matters: Maintaining cash is crucial for operations. A drop could signal financial trouble.
Worry ifCash balance remains above $5M in the next quarterly report.
Less concerning ifCash balance drops below $3M in the next quarterly report.
Why it matters: Updates on cash management are important. They affect funding for operations and trials.
Worry ifThe company says cash levels are stable or increasing before May 2027.
Less concerning ifThe company says cash levels are dropping or plans to raise more money.
Why it matters: The debt conversion helps the balance sheet. This will affect future funding and operations.
Supportive ifManagement says cash flow and funding have improved after the debt conversion.
Worry ifCash flow is still limited even after the debt conversion. This affects operations.
Why it matters: New data can show belapectin works well. This may attract partners and investors.
Supportive ifNew results from the NAVIGATE trial show good outcomes at big conferences.
Worry ifData shows negative results or no important findings from the NAVIGATE trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$296 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $933 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,805 loss on $10,000 · 68.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New biomarker data could show that belapectin works well for MASH cirrhosis. This may affect how investors feel.
Supportive ifThe company shares good biomarker results at a big conference or in a journal.
Worry ifThe analyses show no big improvements or bad results.
Why it matters: Using this credit line shows the company is managing cash needs. It indicates financial health.
Supportive ifThe company reports using at least $3M of the line of credit in the next quarter.
Worry ifThe company does not utilize any of the $10M line of credit in the next quarter.
Why it matters: Having enough cash is key for funding research and development.
Worry ifCash and cash equivalents stay stable or increase, showing good funding.
Less concerning ifCash levels drop a lot, raising worries about funding after mid-2027.
Why it matters: Maintaining cash levels is critical for funding operations through mid-2027. Any shortfall could raise concerns.
Worry ifThe company says it has over $10 million in cash and cash equivalents in Q3 2026.
Less concerning ifCash and cash equivalents drop below $10 million without a clear funding plan.
Why it matters: Submitting the Phase 3 protocol is crucial for advancing belapectin in MASH cirrhosis. This could lead to potential FDA approval.
Supportive ifThe company submits the Phase 3 trial protocol to the FDA by the end of Q3 2026.
Worry ifThe company delays the submission beyond Q3 2026.
Why it matters: Sufficient cash is critical for ongoing operations and R&D. A decline could signal financial strain.
Worry ifCash and cash equivalents fall below $10 million.
Less concerning ifCash and cash equivalents remain above $10 million.